Improved efficiency and cost reduction in the emergency department by replacing contemporary sensitive with high-sensitivity cardiac troponin immunoassay
暂无分享,去创建一个
G. Lippi | G. Cervellin | F. Sanchis-Gomar | I. Comelli | P. Avanzini | R. Aloe | L. Bonfanti | M. Dipalo | M. Di Pietro
[1] M. Pauschinger,et al. [Clinical implications of the fourth universal definition of myocardial infarction]. , 2020, Herz.
[2] G. Lippi. The origin of some laboratory medicine milestones , 2019, Journal of Laboratory and Precision Medicine.
[3] E. Wiens,et al. Routine creatine kinase testing does not provide clinical utility in the emergency department for diagnosis of acute coronary syndromes , 2019, BMC Emergency Medicine.
[4] B. Lindahl,et al. Cardiac Troponin Elevation in Patients Without a Specific Diagnosis. , 2019, Journal of the American College of Cardiology.
[5] G. Lippi,et al. Trends of popularity of cardiac biomarkers: Insights from Google Trends , 2018, Emergency Care Journal.
[6] J. Hollander. High-Sensitivity Troponin: Time to Implement. , 2018, Annals of emergency medicine.
[7] A. Šimundić,et al. Joint EFLM-COLABIOCLI Recommendation for venous blood sampling , 2018, Clinical chemistry and laboratory medicine.
[8] Kristian Thygesen,et al. Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.
[9] G. Lippi,et al. Critical appraisal to using relative or absolute cardiac troponins change for diagnosing acute myocardial infarction , 2018 .
[10] G. Lippi,et al. High-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department , 2017 .
[11] G. Lippi,et al. Clinical, organizational and economic analysis of high-sensitivity cardiac troponin testing in the emergency department , 2017 .
[12] B. Lindahl,et al. Early rule out of acute myocardial infarction , 2017 .
[13] James McCord,et al. Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction , 2017, Journal of the American Heart Association.
[14] G. Lippi,et al. Analytical evaluation of the new Beckman Coulter Access high sensitivity cardiac troponin I immunoassay , 2017, Clinical chemistry and laboratory medicine.
[15] J. Karnon,et al. Cost effectiveness of high-sensitivity troponin compared to conventional troponin among patients presenting with undifferentiated chest pain: A trial based analysis. , 2017, International journal of cardiology.
[16] G. Lippi,et al. High-sensitivity cardiac troponin in the emergency department: The perfect storm? , 2017, International journal of cardiology.
[17] G. Lippi,et al. Diagnostic algorithms for acute coronary syndrome-is one better than another? , 2016, Annals of translational medicine.
[18] G. Lippi,et al. A false positive case of cardiac troponin I identified with CK-MB reflex testing. , 2014, International journal of cardiology.
[19] G. Lippi,et al. Analytical assessment of the Beckman Coulter Unicel DxI AccuTnI+3 immunoassay , 2014, Diagnosis.
[20] G. Lippi,et al. Do we really need high-sensitivity troponin immunoassays in the emergency department? Maybe not , 2014, Clinical chemistry and laboratory medicine.
[21] Mario Plebani,et al. Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation , 2013, Clinical chemistry and laboratory medicine.
[22] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.